Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Cancer Med 2019 Aug 7;8(9):4089-4092. Epub 2019 Jun 7.

Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient-years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675726PMC
August 2019
10 Reads

Publication Analysis

Top Keywords

primary malignancies
8
spm smf
8
second primary
8
smf
5
smf patients
4
myelofibrosis smf
4
patients incidence
4
incidence spm
4
occurrence findings
4
secondary myelofibrosis
4
smf diagnosis
4
merged mysec
4
associated nmsc
4
general population
4
smf subanalysis
4
population mysec
4
mysec study
4
occurrence merged
4
study 781
4
findings highlight
4

Similar Publications